Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Metastatic Castration-resistant Prostate Cancer × ebastine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Metastatic Castration-resistant Prostate Cancer 1

Interventions

darolutamide 3 testosterone 17 beta-cypionate 2 Pluvicto 2 Docetaxel 2 sipuleucel-T 1 sarilumab 1 lactitol 1 fludarabine phosphate 1 fludarabine 1 enzalutamide 1 ebastine 1 cemiplimab 1 cabazitaxel 1 Standard of Care 1 PSMA-617 1 Gonadotropin-Releasing Hormone 1 Cyclophosphamide 1 Bortezomib 1 Blood Specimen Collection 1 Androgen Antagonists 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06480110 2025-04-13

Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer

Rigshospitalet, Denmark

Phase 1/2 Recruiting

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡